Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
Public ClinicalTrials.gov record NCT05615948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
Study identification
- NCT ID
- NCT05615948
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 15 participants
Conditions and interventions
Conditions
- Treatment Resistant Depression
- Major Depressive Disorder
- Analgesia
- Ketamine
- Peripheral Nervous System Agents
- Central Nervous System Depressants
- Neurotransmitter Agents
- Anti-Inflammatory Agents
- Physiological Effects of Drugs
- Sensory System Agents
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents, Non-Steroidal
- Depressive Symptoms
Eligibility (public fields only)
- Age range
- 18 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2022
- Primary completion
- May 16, 2024
- Completion
- May 16, 2024
- Last update posted
- Apr 20, 2026
2022 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Maimonides Medical Center | Brooklyn | New York | 11219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Treatment Resistant Depression trials
Other public records listing Treatment Resistant Depression. Sorted by last update posted; newest first. Not a recommendation.
- NCT06002204: Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression Active, not recruiting
- NCT03952962: Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression Recruiting
- NCT06480201: Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression Recruiting
- NCT05849402: Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder Active, not recruiting
- NCT05774665: Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression Active, not recruiting
- NCT07227103: A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05615948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05615948 live on ClinicalTrials.gov.